Abstract | AIMS: METHODS AND RESULTS: We surveyed MAGE-A and NY-ESO-1 expression in an unselected cohort of 367 breast tumours (of which 65 were TN), with accompanying clinical follow-up data, by using immunohistochemical analysis of tissue microarrays. Relevant to their potential as vaccine targets in breast cancer, MAGE-A was expressed in 13% of cases, and NY-ESO-1 in 3.8%, with the majority of tumours showing fairly homogeneous staining within individual tissue cores (~85% of cases with staining in >75% of tumour cells). Most NY-ESO-1-positive cases also expressed MAGE-A (P = 2.06 × 10-9 ), and both were strongly associated with the TN phenotype (P < 0.0001), with the most proliferative and poorly differentiated cases, in paticular, showing genomic instability. This was characterised by coexpression of c-Kit and TTK, and overexpression of p53. CONCLUSIONS: MAGE-A and NY-ESO-1 are frequently expressed in TN breast cancer (~47% and 17% of TN cases, respectively), suggesting that targeting them could be feasible in this patient group. Expression is reasonably homogeneous in positive cases, suggesting that immunohistochemical analysis of tissue biopsies would be a reliable companion biomarker.
|
Authors | Ashwini Raghavendra, Priyakshi Kalita-de Croft, Ana C Vargas, Chanel E Smart, Peter T Simpson, Jodi M Saunus, Sunil R Lakhani |
Journal | Histopathology
(Histopathology)
Vol. 73
Issue 1
Pg. 68-80
(Jul 2018)
ISSN: 1365-2559 [Electronic] England |
PMID | 29465777
(Publication Type: Journal Article)
|
Copyright | © 2018 The Authors. Histopathology published by John Wiley & Sons Ltd. |
Chemical References |
- Antigens, Neoplasm
- Biomarkers, Tumor
- CTAG1B protein, human
- Melanoma-Specific Antigens
- Membrane Proteins
|
Topics |
- Adult
- Antigens, Neoplasm
(biosynthesis)
- Biomarkers, Tumor
(analysis)
- Female
- Humans
- Melanoma-Specific Antigens
(biosynthesis)
- Membrane Proteins
(biosynthesis)
- Middle Aged
- Retrospective Studies
- Triple Negative Breast Neoplasms
(metabolism, pathology)
|